Whack-a-Mole: Testing an Intervention to Increase Melanoma Identification

Diagnoses Disease Clinical Trial

Official title:

Whack-a-Mole: Testing an Intervention to Increase Melanoma Identification

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04069104
• Other study ID #: 20190153
• Status: Completed
• Start date: November 13, 2020
• Est. completion date: March 3, 2021

Study information

• Verified date: October 2021
• Source: University of Miami
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate an interactive game designed to increase people's ability to identify cancerous moles.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1849
• Est. completion date: March 3, 2021
• Est. primary completion date: March 3, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Resident of U.S.

• At least 18 years old

• Capable of reading English

• Member of panel assembled by survey provider

Exclusion Criteria:

• Individuals under 18 years old

Related Conditions & MeSH terms

• Diagnoses Disease
• Melanoma

Intervention

Behavioral:
• ABCD Information
The intervention condition includes exposure to a message emphasizing the ABCD strategy to identify malignant melanoma.
• UDS information
The intervention condition includes exposure to a message emphasizing the UDS strategy to identify malignant melanoma.
• Standard (clinical) feedback
Feedback on mole identification task provided by a dermatologist.
• Motivational feedback
Feedback on mole identification task provided by a dermatologist plus exposure to a motivational fear appeal message designed to increase skin self exam intentions.

Locations

Country	Name	City	State
United States	University of Miami	Coral Gables	Florida

Sponsors (1)

Lead Sponsor	Collaborator
University of Miami

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mole identification accuracy	Mole identification accuracy will be reported as the amount of mole correctly identified as either melanoma or typical nevi	Day 2
Secondary	Skin Self Exam Intentions	Self-report measure of intentions to perform a skin self exam. Quantified using a single item indicator with scores ranging from 1-7 with higher scores indicating greater intentions to perform a skin self exam to detect potential melanomas.	Day 2
Secondary	Intentions to see a Dermatologist	Self-report measure of intentions to schedule an appointment with a dermatologist to receive a skin cancer exam. Quantified using a single item indicator with scores ranging from 1-7 with higher scores indicating greater intentions to schedule an appointment with a dermatologist.	Day 2
Secondary	Skin Self Exam Attitudes	Self-report measure of attitudes towards skin cancer exams. Quantified using the mean of the self report scale with scores ranging from 1-7 with higher scores indicating more positive attitudes towards skin self exams.	Day 2
Secondary	Skin Self Exam Beliefs	Self-report measure of beliefs towards skin cancer exams. Quantified using the mean of the self report scales for perceived susceptibility, perceived severity, perceived self-efficacy, and perceived response efficacy with scores ranging from 1-7 with higher scores indicating more strongly held beliefs about skin self exams.	Day 2